HIV vaccine trial participation among ethnic minority communities - Barriers, motivators, and implications for recruitment

被引:114
作者
Newman, PA
Duan, N
Roberts, KJ
Seiden, D
Rudy, ET
Swendeman, D
Popova, S
机构
[1] Univ Toronto, Fac Social Work, Toronto, ON M5S 1A1, Canada
[2] Univ Calif Los Angeles, Ctr Community Hlth, Semel Inst Neurosci & Human Behav, Los Angeles, CA USA
[3] Univ Calif Los Angeles, Dept Sociol, Los Angeles, CA 90024 USA
[4] Los Angeles Cty Dept Hlth, Div Sexually Transmitted Dis, Los Angeles, CA USA
关键词
HIV vaccine trial; research participation; barriers; African Americans; Latinos; qualitative research;
D O I
10.1097/01.qai.0000179454.93443.60
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Underrepresentation of ethnic minority communities limits the generalizability of HIV vaccine trial results. We explored perceived barriers and motivators regarding HIV vaccine trial participation among low-socioeconomic ethnic minority respondents at risk for HIV. Methods: Six focus group interviews were conducted using a semistructured interview guide. Participants (N = 58, mean age = 36 years, 37% female, and 56% Latino/a and 35% African American) were recruited using venue-based sampling in Los Angeles. Data were analyzed using narrative thematic analysis and Ethnograph qualitative software. Results: Perceived barriers to HIV vaccine trial participation, in rank order, were (1) vaccine-induced HIV infection, (2) physical side effects, (3) uncertainty about vaccine efficacy, (4) uncertainty about other vaccine characteristics, (5) mistrust, (6) low perceived HIV risk, (7) study demands, (8) stigma, and (9) vaccine-induced HIV seropositivity. Motivators were (1) protection against HIV infection, (2) free insurance and/or medical care, (3) altruism, and (4) monetary incentives. Conclusions: Population-specific HIV vaccine trial recruitment and implementation strategies should address trial risks from a family perspective, cultural gender norms, mistrust, low perceived HIV risk, the importance of African-American and Latino/a community participation in HIV vaccine trials, and misconceptions about gaining protection against HIV infection. Increasing the cultural relevance of trial recruitment and implementation should facilitate the participation of Latinos/as and African Americans in HIV vaccine trials.
引用
收藏
页码:210 / 217
页数:8
相关论文
共 57 条
[1]  
AIRHIHENBUWA CO, 1992, AIDS EDUC PREV, V4, P267
[2]   Assessment of the changing willingness to participate in phase III HIV vaccine trials among men who have sex with men [J].
Bartholow, BN ;
MacQueen, KM ;
Douglas, JM ;
Buchbinder, S ;
McKirnan, D ;
Judson, FN .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1997, 16 (02) :108-115
[3]   COMPLIANCE IN CLINICAL-TRIALS [J].
BESCH, CL .
AIDS, 1995, 9 (01) :1-10
[4]   Involving women in HIV vaccine efficacy trials: Lessons learned from a vaccine preparedness study in New York City [J].
Brown-Peterside, P ;
Chiasson, MA ;
Ren, L ;
Koblin, B .
JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE, 2000, 77 (03) :425-437
[5]   Feasibility of human immunodeficiency virus vaccine trials in homosexual men in the United States: Risk behavior, seroincidence, and willingness to participate [J].
Buchbinder, SP ;
Douglas, JM ;
McKirnan, DJ ;
Judson, FN ;
Katz, MH ;
MacQueen, KM .
JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (05) :954-961
[6]   Determinants of enrollment in a preventive HIV vaccine trial [J].
Buchbinder, SP ;
Metch, B ;
Holte, SE ;
Scheer, S ;
Coletti, A ;
Vittinghoff, E .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 36 (01) :604-612
[7]   Public health - A sound rationale needed for phase IIIHIV-1 vaccine trials [J].
Burton, DR ;
Desrosiers, RC ;
Doms, RW ;
Feinberg, MB ;
Gallo, RC ;
Hahn, B ;
Hoxie, JA ;
Hunter, E ;
Korber, B ;
Landay, A ;
Lederman, MM ;
Lieberman, J ;
McCune, JM ;
Moore, JP ;
Nathanson, N ;
Picker, L ;
Richman, D ;
Rinaldo, C ;
Stevenson, M ;
Watkins, DI ;
Wolinsky, SM ;
Zack, JA .
SCIENCE, 2004, 303 (5656) :316-316
[8]  
*CDCP, 2003, 200415 CDCP HIVAIDS
[9]  
Centers for Disease Control and Prevention (CDC), 2000, MMWR Morb Mortal Wkly Rep, V49, P4
[10]   HIV/AIDS - Vaccine results lose significance under scrutiny [J].
Cohen, J .
SCIENCE, 2003, 299 (5612) :1495-1495